← Leaderboards
Emek Demir
Oregon Health & Science University
$947,940
Attributed
$3,369,952
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2018–23$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$14,451,520 · 4
By mechanism
U54$8,411,251 · 1
U01$2,948,146 · 1
U2C$2,670,317 · 1
U24$421,806 · 1
Top collaborators
- Rosalie C Sears11 shared
- Claire J Tomlin6 shared
- Jonathan Brody5 shared
- Lisa M Coussens5 shared
- Joe W. Gray5 shared
- Gordon B. Mills3 shared
- George Victor Thomas2 shared
- Laura Madeline Heiser1 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jeffrey Wallace Tyner$13,872,769
- George Victor Thomas$5,625,841
- Lisa M Coussens$10,998,130
- Kyle Ellrott$3,673,219
- Adam Arne Margolin$1,948,167
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsTumorMalignant NeoplasmsResistanceMolecularSpecimenEnsureCellsTargeted TreatmentCommunitiesPeriodicityMultidisciplinaryResponsePharmaceutical PreparationsMetadataPhenotypeCancer CellIn VivoComplexBioprinting3-DimensionalGenomicsSamplingStructure
Grant awards (14)
Omic and Multidimensional Spatial Atlas of Metastatic Breast Cancer$923,254
U2C · FY2023 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$546,688
U01 · FY2023 · CA
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,747,063
U2C · FY2022 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$547,032
U01 · FY2022 · CA
Measuring, Modeling and Controlling Heterogeneity$1,851,265
U54 · FY2021 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$714,330
U01 · FY2021 · CA
Measuring, Modeling and Controlling Heterogeneity$2,053,370
U54 · FY2020 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$560,027
U01 · FY2020 · CA
OHSU Center for Specialized Data Analysis as part of the GDAN$421,806
U24 · FY2020 · CA
Measuring, Modeling and Controlling Heterogeneity$2,164,435
U54 · FY2019 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$580,069
U01 · FY2019 · CA
Measuring, Modeling and Controlling Heterogeneity$83,652
U54 · FY2019 · CA
Measuring, Modeling and Controlling Heterogeneity$2,191,539
U54 · FY2018 · CA
Measuring, Modeling and Controlling Heterogeneity$66,990
U54 · FY2018 · CA